Payment overview · 2025
General Payments
$390.03
26 reported records · 8 companies
Healthcare provider profile · identity verified
Tara B Enlow, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FULTON, MS · NPI 1336266550
Verified facts
What the public records show
CMS Open Payments records show Tara B Enlow, CFNP received $390.03 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.41 | 37.8% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.40 | 16.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.69 | 14.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.83 | 13.8% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.24 | 4.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.52 | 4.5% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $16.93 | 4.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.01 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $390.03 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $109.64 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $62.40 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.69 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.77 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.95 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 249 | 53 |
| Montelukast Sodium | Montelukast Sodium | 202 | 71 |
| Metformin Hcl Er | Metformin Hcl | 196 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 48 |
| Meloxicam | Meloxicam | 160 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 47 |
| Omeprazole | Omeprazole | 154 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 136 | 39 |
| Lisinopril | Lisinopril | 134 | 36 |
| Losartan Potassium | Losartan Potassium | 125 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 37 |
| Famotidine | Famotidine | 113 | 47 |
| Fenofibrate | Fenofibrate | 103 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 33 |
| Sertraline Hcl | Sertraline Hcl | 84 | 20 |
| Furosemide | Furosemide | 77 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 35 |
| Buspirone Hcl | Buspirone Hcl | 75 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 53 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Prednisone | Prednisone | 66 | 37 |
| Pregabalin | Pregabalin | 64 | 18 |
| Fluconazole | Fluconazole | 62 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 19 |
| Allopurinol | Allopurinol | 54 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 14 |
| Kerendia | Finerenone | 51 | 11 |
| Promethazine Hcl | Promethazine Hcl | 51 | 13 |
| Farxiga | Dapagliflozin Propanediol | 50 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Tramadol Hcl | Tramadol Hcl | 49 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 16 |
| Eliquis | Apixaban | 47 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 16 |
| Ibuprofen | Ibuprofen | 43 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Carvedilol | Carvedilol | 42 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Methocarbamol | Methocarbamol | 41 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Nystatin | Nystatin | 38 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 14 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Metformin Hcl | Metformin Hcl | 37 | 12 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 12 |
| Levofloxacin | Levofloxacin | 33 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 11 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Amoxicillin | Amoxicillin | 29 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 19 |
| Linzess | Linaclotide | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 13 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Cephalexin | Cephalexin | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Permethrin | Permethrin | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $390.03 · 26 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, JARDIANCE, NURTEC ODT, Ozempic, QULIPTA, Quviviq, Rybelsus, UBRELVY, VRAYLAR, Vest Therapy Und | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error